Bolt Biotherapeutics. has filed a patent for immunoconjugates comprising anti-PD-L1 antibodies linked to 8-Cyc-2-aminobenzazepine derivatives. The invention aims to treat cancer by utilizing these immunoconjugates. GlobalData’s report on Bolt Biotherapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Bolt Biotherapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Bolt Biotherapeutics, Nanoparticle drug conjugates was a key innovation area identified from patents. Bolt Biotherapeutics's grant share as of January 2024 was 6%. Grant share is based on the ratio of number of grants to total number of patents.

Immunoconjugates for cancer treatment with anti-pd-l1 antibody

Source: United States Patent and Trademark Office (USPTO). Credit: Bolt Biotherapeutics Inc

A recently filed patent (Publication Number: US20240033370A1) discloses an immunoconjugate comprising an antibody covalently attached to one or more 8-Cyc-2-aminobenzazepine moieties by a linker. The immunoconjugate is designed to target PD-L1, a protein involved in cancer immune evasion. The patent claims specify the structure of the immunoconjugate, including the antibody constructs, linker molecules, and specific amino acid sequences. The patent also covers the use of the immunoconjugate in treating various cancers, such as bladder cancer, lung cancer, colorectal cancer, and breast cancer, particularly those susceptible to a pro-inflammatory response induced by TLR7 and/or TLR8 agonism.

Furthermore, the patent details the preparation of the immunoconjugate, including the conjugation of the anti PD-L1 antibody with the 8-Cyc-2-aminobenzazepine-linker compound. The pharmaceutical composition comprising the immunoconjugate and its administration methods are also described in the patent claims. The immunoconjugate can be administered intravenously, intratumorally, or subcutaneously at a specified dose range. The patent highlights the potential applications of the immunoconjugate in treating specific types of cancers, such as triple-negative breast cancer, metastatic Merkel cell carcinoma, and gastroesophageal junction adenocarcinoma. Overall, the patent provides a detailed framework for the development and use of the immunoconjugate in cancer therapy, emphasizing its potential in targeting PD-L1-expressing cancers and inducing a pro-inflammatory response for effective treatment.

To know more about GlobalData’s detailed insights on Bolt Biotherapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies